Microbion Corporation
3 News & Press Releases found

Microbion Corporation news

Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the pravibismane program with this latest patent providing protection through to 2039. This patent family is pe

Oct. 1, 2022

Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and biofilm phenotypes. Financial support for this study was provided by CARB-X.

The poster, t

Oct. 1, 2022

Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, Broad Spectrum Anti-Infective Wound Care Treatment and Prevention for Combat Injury-Related Infectio

Jun. 1, 2022

Contact supplier

Drop file here or browse